User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 3 results.
    • Journal article
    Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber, Thomas Reich, Kristian Paul, Carle Tsunemi, Yuichiro Augustin, Matthias Lacour, Jean-Philippe Ghislain, Pierre-Dominique[UCL] Dutronc, Yves Liao, Ran Yang, Fan E Brinker, Dennis DeLozier, Amy M Meskimen, Eric Janes, Jonathan M Eyerich, Kilian BREEZE-AD4 study group (2022) The British journal of dermatology — Vol. 187, no.3, p. 338-352 (2022)
    • Journal article
    ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre, Pierre-François[UCL] Abraham, Edward Janes, Jonathan M Trzaskoma, Benjamin Correll, Nancy L Booth, Frank V (2007) Critical care medicine — Vol. 35, no. 6, p. 1457-63 (2007)
    • Journal article
    Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
    Shorr, Andrew F Janes, Jonathan M Artigas, Antonio Tenhunen, Jyrki Wyncoll, Duncan L A Mercier, Emmanuelle Francois, Bruno Vincent, Jean-Louis Vangerow, Burkhard Heiselman, Darell Leishman, Amy G Zhu, Yajun E Reinhart, Konrad RESPOND investigators Laterre, Pierre-François[UCL] (2010) Critical Care — Vol. 14, no.6, p. R229 [1-14] (2010)